
Orsolya Anna Pipek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1489543/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell, 2018, 173, 595-610.e11.	28.9	472
2	A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biology, 2016, 17, 99.	8.8	150
3	Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene, 2017, 36, 746-755.	5.9	98
4	Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1219-1226.	2.5	58
5	Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. Neuro-Oncology, 2017, 19, 1058-1067.	1.2	38
6	PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis. Clinical Lung Cancer, 2019, 20, 363-369.e2.	2.6	28
7	Fast and accurate mutation detection in whole genome sequences of multiple isogenic samples with IsoMut. BMC Bioinformatics, 2017, 18, 73.	2.6	26
8	Expression patterns and prognostic relevance of subtypeâ€specific transcription factors in surgically resected smallâ€cell lung cancer: an international multicenter study. Journal of Pathology, 2022, 257, 674-686.	4.5	26
9	The Genome of the Chicken DT40 Bursal Lymphoma Cell Line. G3: Genes, Genomes, Genetics, 2014, 4, 2231-2240.	1.8	25
10	New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study. Lung Cancer, 2018, 126, 139-148.	2.0	25
11	Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma. Acta Oncológica, 2019, 58, 1087-1094.	1.8	22
12	Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts. British Journal of Cancer, 2018, 119, 1392-1400.	6.4	19
13	EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study. Translational Lung Cancer Research, 2021, 10, 662-674.	2.8	17
14	S-Adenosylmethionine Treatment of Colorectal Cancer Cell Lines Alters DNA Methylation, DNA Repair and Tumor Progression-Related Gene Expression. Cells, 2020, 9, 1864.	4.1	16
15	The landscape of small cell lung cancer metastases: Organ specificity and timing. Thoracic Cancer, 2021, 12, 914-923.	1.9	14
16	Worldwide human mitochondrial haplogroup distribution from urban sewage. Scientific Reports, 2019, 9, 11624.	3.3	12
17	Nationwide lung cancer screening with low-dose computed tomography: implementation and first results of the HUNCHEST screening program. European Radiology, 2022, 32, 4457-4467.	4.5	9
18	Folic Acid Treatment Directly Influences the Genetic and Epigenetic Regulation along with the Associated Cellular Maintenance Processes of HT-29 and SW480 Colorectal Cancer Cell Lines. Cancers, 2022, 14, 1820.	3.7	5

#	Article	IF	CITATIONS
19	The genomic imprint of cancer therapies helps timing the formation of metastases. International Journal of Cancer, 2019, 145, 694-704.	5.1	4
20	Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 126-132.	2.5	2
21	FcRn Overexpression Expands Diversity of the Humoral Immune Response in bFcRn Transgenic Mice. Frontiers in Immunology, 2020, 11, 1887.	4.8	2
22	Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes. Cancers, 2022, 14, 1942.	3.7	2
23	P1.06-012 Central and Peripheral Lung Adenocarcinomas Exhibit Different Timing and Predilection for Distant Metastasis. Journal of Thoracic Oncology, 2017, 12, S671-S672.	1.1	0
24	Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis. Basic and Clinical Pharmacology and Toxicology, 2017, 122, 126.	2.5	0